Drug Trial Radar · NCT07927972
Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Subcutaneous Injections of Elamipretide in Pediatric Subjects With Barth Syndrome
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
6
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
May 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Stealth BioTherapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1, open-label trial will enroll approximately 6 subjects who have BTHS weighing between 7 and 30 kg. Subjects will receive a weight-based dose of elamipretide daily via SC injection for 4 weeks. PK samples will be collected on Day 1 and at week 4 to determine PK profile in BTHS patients weighing between 7 and 30kg.
Conditions
- Barth Syndrome
Interventions
ElamipretideDrug
SC injection daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum plasma concentration of elamipretide and its metabolitesTime frame: 24 hours
- Area under the plasma concentration time curve from 0 to 24 hoursTime frame: 24 hours
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama Birmingham Medical Center
Birmingham, Alabama
Stanford University School of Medicine Pediatrics
Palo Alto, California
OSF St. Francis Medical Center
Peoria, Illinois
Children's Nebraska
Omaha, Nebraska
Ichan School of Medicine at Mount Sinai
New York, New York
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
UTSW: Children's Medical Center Pediatrics
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.